InsiderPulse
Dashboard

TWST

Twist Bioscience Corporation

Health CareRussell 2000

Twist Bioscience Corporation insider trading

Twist Bioscience Corporation files with the SEC as a Biological Products, (No Diagnostic Substances) company headquartered in South San Francisco, CA. Every time one of its executives or directors buys or sells the stock, the filing appears here the moment it reaches the SEC — with grants and option exercises set apart from the trades that cost the insider their own money.

From SEC filings

Recent TWST insider transactions

4 insiders traded TWST on the open market between Aug 21, 2026 and Sep 17, 2026 — 24 sales worth $63.5M, of which 18 were pre-scheduled under a 10b5-1 plan.

Bought
—
Sold
$63.5M

18 of 24 on a 10b5-1 plan

Net
−$63.5M
Insiders
4

Open-market purchases (code P) and sales (code S) from Twist Bioscience Corporation's own SEC Form 4 filings. Grants and option exercises are excluded — they are compensation, not decisions. Share counts are derived from the reported value and price. Verify any figure against the original filing before acting on it; this is monitoring, not advice.

Filing history last read from EDGAR on Sep 22, 2026. The live dashboard shows new filings the moment they clear.

Every TWST Form 4 on SEC.gov

SEC Form 4 data, Q3 2024 to Q2 2026

TWST insider trading by quarter

Between Jul 01, 2024 and Jun 30, 2026, 9 insiders traded TWST on the open market: 0 purchases and 256 sales worth $42.1M, 38 of the sales pre-scheduled under a 10b5-1 plan. In the last four quarters alone: 0 purchases and 146 sales ($32.5M), by 9 insiders.

QuarterBoughtSold
Q2 2026—−$15.5M46 sales · 20 on a plan
Q1 2026—−$10.3M35 sales · 11 on a plan
Q4 2025—−$5.8M39 sales · 2 on a plan
Q3 2025—−$879.3K26 sales
Q2 2025—−$1.8M28 sales
Q1 2025—−$1.9M28 sales · 1 on a plan
Q4 2024—−$4.9M34 sales · 4 on a plan
Q3 2024—−$957.9K20 sales
Largest sale
−$2.1M of TWST by Green Paula (SVP of Human Resources) on Feb 17, 2026.

Open-market transactions through Jun 30, 2026most recent first

  • Leproust Emily M.10b5-1

    Chief Executive Officer · Director

    −$1.8M

    Jun 25, 2026

    18,880 sh · $95.00

  • Cho Dennis10b5-1

    Officer

    −$1.3M

    Jun 24, 2026

    14,205 sh · $89.75

  • Leproust Emily M.

    Chief Executive Officer · Director

    −$147.4K

    Jun 22, 2026

    1,688 sh · $87.32

  • Cho Dennis

    Officer

    −$30.2K

    Jun 22, 2026

    346 sh · $87.32

  • Green Paula

    SVP of Human Resources

    −$25.4K

    Jun 22, 2026

    291 sh · $87.32

  • Green Paula

    SVP of Human Resources

    −$2M

    Jun 15, 2026

    24,109 sh · $81.62

  • Green Paula

    SVP of Human Resources

    −$166.6K

    Jun 15, 2026

    2,028 sh · $82.17

  • Leproust Emily M.

    Chief Executive Officer · Director

    −$158.2K

    Jun 08, 2026

    2,265 sh · $69.84

  • Werner Robert F.

    Chief Accounting Officer

    −$77.8K

    Jun 08, 2026

    1,127 sh · $69.07

  • Green Paula

    SVP of Human Resources

    −$61.7K

    Jun 08, 2026

    884 sh · $69.84

  • Cho Dennis

    Officer

    −$28.1K

    Jun 08, 2026

    402 sh · $69.84

  • Werner Robert F.

    Chief Accounting Officer

    −$16.2K

    Jun 08, 2026

    232 sh · $69.84

  • Cho Dennis10b5-1

    Officer

    −$990.8K

    May 29, 2026

    14,205 sh · $69.75

  • Laponis Adam10b5-1

    Chief Financial Officer

    −$280K

    May 29, 2026

    4,000 sh · $70.00

  • Leproust Emily M.10b5-1

    Chief Executive Officer · Director

    −$518K

    May 28, 2026

    7,623 sh · $67.95

From SEC's quarterly Form 3, 4 and 5 data sets: code P purchases and code S sales of common stock, by the date the trade happened. Where a fund and the people who control it each report the same block, it is counted once. Trades made in the last days of Q2 2026 but filed after it closed arrive with SEC's next quarterly release.

Twist Bioscience Corporation company record

SEC industry classification
Biological Products, (No Diagnostic Substances)
Headquarters
South San Francisco, CA
Incorporated in
DE
Listed on
Nasdaq
SEC Central Index Key
0001581280

Sourced from this company's own SEC submissions record. The industry label is SEC's Standard Industrial Classification, which is more specific than the Health Care sector shown above.

After insiders bought TWST

What the stock actually did in the 90 days following each open-market purchase

Don't check TWST — let it ping you

Get told the moment an insider moves on TWST

Pro watches Twist Bioscience Corporation for you and sends a Telegram ping within moments of a Form 4 clearing EDGAR — a C-suite open-market buy, a cluster, a 10b5-1 regime break — long before it reaches the press. Add TWST to a watchlist, see each mover's benchmark-measured track record and which legendary funds hold it, and read the full filing history instead of the last 72 hours.

Track TWST on the live dashboardFilings on SEC.gov

The live dashboard is free to open. Alerts, watchlists, full filing history and each mover's benchmark-measured track record are Pro. Monitoring, not advice.

How to read TWST insider activity

Open-market purchase (code P)
An insider spending their own money at market price. This is the only buy code that reliably carries signal — it is a decision, not compensation.
Grants and option exercises (codes A, M)
Scheduled compensation. Most "insider buying" headlines are really this, which is why InsiderPulse weights it at a fraction of a real purchase.
Cluster buy
Two or more different insiders buying on the open market in the same window. One executive buying can mean anything; three is much harder to explain away.

Other Health Care tickers

PACBARWRIONSAXSMKRYSRAREFOLDACADPTCTMEDPDNLIVEEV
This week on the tape: who actually chose to sellThe weekly split of scheduled 10b5-1 selling vs deliberate sales, with the deciders named.

Questions

Are TWST insiders buying or selling?
Between Aug 21, 2026 and Sep 17, 2026, 4 Twist Bioscience Corporation insiders made no open-market purchases and 24 sales worth $63.5M, a net sale of $63.5M. 18 of the sales were pre-scheduled under a Rule 10b5-1 plan.
How much TWST stock have insiders bought and sold in the last two years?
Between Jul 01, 2024 and Jun 30, 2026, 9 Twist Bioscience Corporation insiders made no open-market purchases and 256 sales worth $42.1M. 38 of the sales were pre-scheduled under a Rule 10b5-1 plan. In the four quarters to Jun 30, 2026: no purchases and 146 sales ($32.5M). The largest sale was Green Paula selling $2.1M on Feb 17, 2026.
What was the largest recent TWST insider trade?
Leproust Emily M. (Chief Executive Officer · Director) sold $36.7M of TWST stock on Sep 17, 2026 at about $158.09 a share, under a pre-scheduled 10b5-1 plan.
When did an insider last buy TWST shares?
No open-market purchase by a Twist Bioscience Corporation insider appears in the filings from Aug 21, 2026 to Sep 17, 2026 — every recorded open-market transaction in that period was a sale.
Where does TWST insider trading data come from?
From the Form 4 filings Twist Bioscience Corporation's officers, directors and 10% owners must send the SEC within two business days of a trade. Each row on this page links to its original filing on SEC EDGAR. Share grants and option exercises are kept apart from open-market purchases and sales, because only the latter cost the insider their own money.

Get the free Insider Brief

Each weekday evening: the day's biggest open-market insider buys, cluster formations and 10b5-1 plan breaks — in plain English, with grants and routine vesting stripped out. Honest about what the data can and cannot say.

No account needed. One-click unsubscribe.